Protara Therapeutics (NASDAQ:TARA – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.37, Zacks reports.
Protara Therapeutics Stock Performance
Shares of TARA stock remained flat at $1.90 during mid-day trading on Thursday. 107,992 shares of the company’s stock traded hands, compared to its average volume of 233,772. The stock has a market capitalization of $39.12 million, a PE ratio of -0.51 and a beta of 1.85. Protara Therapeutics has a 1-year low of $1.04 and a 1-year high of $5.24. The stock’s 50-day moving average price is $2.34 and its two-hundred day moving average price is $2.99.
Insiders Place Their Bets
In other news, major shareholder Opaleye Management Inc. sold 11,396 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $2.44, for a total transaction of $27,806.24. Following the transaction, the insider now owns 56,500 shares in the company, valued at $137,860. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 248,588 shares of company stock valued at $671,847. 12.50% of the stock is currently owned by insiders.
Analyst Ratings Changes
Check Out Our Latest Analysis on Protara Therapeutics
About Protara Therapeutics
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Featured Stories
- Five stocks we like better than Protara Therapeutics
- What is a Bond Market Holiday? How to Invest and Trade
- Owens-Corning Stock: Good Value or Recession Red Flag?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- How to Use Stock Screeners to Find Stocks
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.